1. Treatment of Symptomatic Benign Prostatic Hyperplasia: Current and Future Clinical Practice in Europe – What is Really Happening? 
Bob Djavan 
European Urology Supplements 
Volume 6, Issue 6, Pages (March 2007)
DOI: /j.eursup
Copyright © Terms and Conditions

2. Fig. 1
Use of watchful waiting and medication types in the Trans European Research into the Use of Management Policies for BPH in Primary Healthcare study [5]. Patients could have received more than one therapy.
European Urology Supplements 2007 6, DOI: ( /j.eursup )
Copyright © Terms and Conditions

3. Fig. 2
Cumulative progression rates to moderate and severe symptom groups in men with clinical progression from a longitudinal study of men with mild symptoms of bladder outlet obstruction treated with watchful waiting for 4 yr (n=397) [20].
European Urology Supplements 2007 6, DOI: ( /j.eursup )
Copyright © Terms and Conditions

4. Fig. 3
Type 1 and type 2 5α-reductase mRNA expression in normal prostate, benign prostatic hyperplasia, and prostate cancer tissues using reverse transcription-polymerase chain reaction [27]. BPH=benign prostatic hyperplasia; PCa=prostate cancer; CZ=central zone; PZ=peripheral zone; TBP=TATA-binding protein; TZ=transitional zone.
European Urology Supplements 2007 6, DOI: ( /j.eursup )
Copyright © Terms and Conditions